Prodo Laboratories, Inc. and Invenio Institute Launched as New Diabetes Research Companies
Two new diabetes companies, Prodo Laboratories, Inc. and Invenio Institute, announced their launch at the Rachmiel Levine Diabetes and obesity Symposium. Prodo Laboratories, Inc., a privately held biopharmaceutical company located in Irvine, CA, will provide primary human islets as a research service to corporate investigators and will offer islet research tissue culture media, reagents, and factors to diabetes researchers. In addition to pursuing its own research programs, it will also provide small company incubator opportunities in diabetes. Invenio Institute, a California public benefit company also in Irvine, CA, is a new diabetes research institute that will begin providing human islets to academic researchers as it builds its diabetes research program.
David W. Scharp, MD, Founder, President, and Chief Executive Officer of both new companies, stated: "These two companies will focus their initial efforts on increasing the availability of primary human islets for research and providing high quality research reagents to diabetes investigators. It is important to build these two new diabetes companies now with the serious increase in the incidence of diabetes in the world's population, driving a critical need for new research efforts."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
